Seborrhoeic Dermatitis - Pipeline Insight, 2024

Seborrhoeic Dermatitis - Pipeline Insight, 2024

DelveInsight’s, “Seborrhoeic Dermatitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Seborrhoeic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Seborrhoeic Dermatitis Understanding

Seborrhoeic Dermatitis: Overview

Seborrheic dermatitis is a chronic inflammatory dermatologic condition that usually affects the areas of the body with a large density of sebaceous glands, such as the scalp, face, chest, back, axilla, and groin. Overall, it has been reported to affect about 4% of the population. The cause of seborrheic dermatitis is not completely understood but it is thought to be triggered by the overgrowth of a harmless yeast called Malassezia that lives on the skin, or an overreaction by the skin’s immune system to this yeast. The diagnosis is based on the location and appearance of rash or lesion. Skin biopsy may be helpful but is rarely indicated. Seborrhoeic dermatitis is managed with treatment that reduces the level of skin yeast – these include creams and shampoo, which can be used safely on a long-term basis.

""Seborrhoeic Dermatitis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Seborrhoeic Dermatitis pipeline landscape is provided which includes the disease overview and Seborrhoeic Dermatitis treatment guidelines. The assessment part of the report embraces, in depth Seborrhoeic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Seborrhoeic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Seborrhoeic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Seborrhoeic Dermatitis.

Seborrhoeic Dermatitis Emerging Drugs Chapters

This segment of the Seborrhoeic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Seborrhoeic Dermatitis Emerging Drugs

• Topical roflumilast foam (ARQ-154): Arcutis Biotherapeutics

Topical roflumilast foam (ARQ-154) is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has shown greater potency based on IC50 values (a non-clinical measure of a drug’s potency) than any other disclosed PDE4 inhibitor. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases. Arcutis has initiated a Phase 2 clinical trial to evaluate topical roflumilast foam for seborrheic dermatitis.

• Omiganan (CLS002): Cutanea Life Sciences

Chitosan (CLS002), an implantable bioresorbable gel based on chitin and chitosan to treat soft tissue abnormalities of the skin. It is in phase II of clinical trials for the treatment of Seborrhoeic Dermatitis.

• DBI-002: DermBiont

Mechanism of Action: Microbiome modulators. The drug is in preclinical studies for the treatment of Seborrhoeic Dermatitis.

• PAC-14028: Amorepacific

PAC-14028 was developed as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. It is known that TRPV1 might be deeply associated with skin permeability barrier function, suggesting that modulation of TRPV1 might be beneficial for the skin disorders with barrier damages. Amorepacific developed a topical cream formulation of PAC-14028. AC-14028 participated in phase II clinical trials to evaluate its safety and efficacy in seborrheic dermatitis

Further product details are provided in the report……..

Seborrhoeic Dermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Seborrhoeic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Seborrhoeic Dermatitis

There are approx. 5+ key companies which are developing the therapies for Seborrhoeic Dermatitis. The companies which have their Seborrhoeic Dermatitis drug candidates in the mid to advanced stage, i.e. Phase II include, Arcutis Biotherapeutics and others.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Seborrhoeic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Parenteral
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Gene Therapy
• Polymer
• Peptides
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Seborrhoeic Dermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Seborrhoeic Dermatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Seborrhoeic Dermatitis drugs.

Seborrhoeic Dermatitis Report Insights

• Seborrhoeic Dermatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Seborrhoeic Dermatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Seborrhoeic Dermatitis drugs?
• How many Seborrhoeic Dermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Seborrhoeic Dermatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Seborrhoeic Dermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Seborrhoeic Dermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcutis Biotherapeutics
• Cutanea Life Sciences
• DermBiont
• Astion Pharma A/S
• Amorepacific

Key Products

• ARQ-154
• CLS002
• DBI-002
• ASF-1057
• PAC-14028